China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise
Posted: 21 Mar 2012
Date Written: February 9, 2012
Abstract
As the head of the Novartis Institute for Biomedical Research in China, En Li was shepherding a $1 billion R&D investment in China. So far he had been able to attract a large number of Chinese-born but US-trained scientists to play a critical role in establishing the site. How sustainable was this strategy, and what were the key things he had to do right to establish a globally integrated R&D unit in China?
Learning Objective: Examine the issues surrounding the establishment of a new R&D facility in China that will be part of a global network.
Suggested Citation: Suggested Citation
Sato, Vicki and Jaeker, Christoph and Solanki, Pooja, China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise (February 9, 2012). Harvard Business School Technology & Operations Mgt. Unit Case No. 612-048, Available at SSRN: https://ssrn.com/abstract=2026575
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.